Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site.

Howell KA, Qiu X, Brannan JM, Bryan C, Davidson E, Holtsberg FW, Wec AZ, Shulenin S, Biggins JE, Douglas R, Enterlein SG, Turner HL, Pallesen J, Murin CD, He S, Kroeker A, Vu H, Herbert AS, Fusco ML, Nyakatura EK, Lai JR, Keck ZY, Foung SK, Saphire EO, Zeitlin L, Ward AB, Chandran K, Doranz BJ, Kobinger GP, Dye JM, Aman MJ.

Cell Rep. 2016 May 17;15(7):1514-26. doi: 10.1016/j.celrep.2016.04.026.

2.

The Iminosugar UV-4 is a Broad Inhibitor of Influenza A and B Viruses ex Vivo and in Mice.

Warfield KL, Barnard DL, Enterlein SG, Smee DF, Khaliq M, Sampath A, Callahan MV, Ramstedt U, Day CW.

Viruses. 2016 Mar 7;8(3):71. doi: 10.3390/v8030071.

3.

Monoclonal antibody therapy for Junin virus infection.

Zeitlin L, Geisbert JB, Deer DJ, Fenton KA, Bohorov O, Bohorova N, Goodman C, Kim D, Hiatt A, Pauly MH, Velasco J, Whaley KJ, Altmann F, Gruber C, Steinkellner H, Honko AN, Kuehne AI, Aman MJ, Sahandi S, Enterlein S, Zhan X, Enria D, Geisbert TW.

Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4458-63. doi: 10.1073/pnas.1600996113.

4.

Inhibition of endoplasmic reticulum glucosidases is required for in vitro and in vivo dengue antiviral activity by the iminosugar UV-4.

Warfield KL, Plummer EM, Sayce AC, Alonzi DS, Tang W, Tyrrell BE, Hill ML, Caputo AT, Killingbeck SS, Beatty PR, Harris E, Iwaki R, Kinami K, Ide D, Kiappes JL, Kato A, Buck MD, King K, Eddy W, Khaliq M, Sampath A, Treston AM, Dwek RA, Enterlein SG, Miller JL, Zitzmann N, Ramstedt U, Shresta S.

Antiviral Res. 2016 May;129:93-8. doi: 10.1016/j.antiviral.2016.03.001.

5.

Development of a novel multiplex electrochemiluminescent-based immunoassay for quantification of human serum IgG against 10 Staphylococcus aureus toxins.

Adhikari RP, Haudenschild C, Sterba PM, Sahandi S, Enterlein S, Holtsberg FW, Aman MJ.

J Immunol Methods. 2016 Mar;430:33-42. doi: 10.1016/j.jim.2016.01.013.

PMID:
26826278
6.

Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.

Keck ZY, Enterlein SG, Howell KA, Vu H, Shulenin S, Warfield KL, Froude JW, Araghi N, Douglas R, Biggins J, Lear-Rooney CM, Wirchnianski AS, Lau P, Wang Y, Herbert AS, Dye JM, Glass PJ, Holtsberg FW, Foung SK, Aman MJ.

J Virol. 2015 Oct 14;90(1):279-91. doi: 10.1128/JVI.02172-15.

7.

A Novel Iminosugar UV-12 with Activity against the Diverse Viruses Influenza and Dengue (Novel Iminosugar Antiviral for Influenza and Dengue).

Warfield KL, Plummer E, Alonzi DS, Wolfe GW, Sampath A, Nguyen T, Butters TD, Enterlein SG, Stavale EJ, Shresta S, Ramstedt U.

Viruses. 2015 May 13;7(5):2404-27. doi: 10.3390/v7052404.

8.

Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names.

Kuhn JH, Andersen KG, Bào Y, Bavari S, Becker S, Bennett RS, Bergman NH, Blinkova O, Bradfute S, Brister JR, Bukreyev A, Chandran K, Chepurnov AA, Davey RA, Dietzgen RG, Doggett NA, Dolnik O, Dye JM, Enterlein S, Fenimore PW, Formenty P, Freiberg AN, Garry RF, Garza NL, Gire SK, Gonzalez JP, Griffiths A, Happi CT, Hensley LE, Herbert AS, Hevey MC, Hoenen T, Honko AN, Ignatyev GM, Jahrling PB, Johnson JC, Johnson KM, Kindrachuk J, Klenk HD, Kobinger G, Kochel TJ, Lackemeyer MG, Lackner DF, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Omilabu SA, Palacios G, Panchal RG, Park DJ, Patterson JL, Paweska JT, Peters CJ, Pettitt J, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire EO, Sabeti PC, Sealfon R, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, Towner JS, van der Groen G, Volchkov VE, Volchkova VA, Wahl-Jensen V, Warren TK, Warfield KL, Weidmann M, Nichol ST.

Viruses. 2014 Sep 26;6(9):3663-82. doi: 10.3390/v6093663.

9.

Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA.

Kuhn JH, Bào Y, Bavari S, Becker S, Bradfute S, Brauburger K, Rodney Brister J, Bukreyev AA, Caì Y, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Gonzalez JP, Formenty P, Freiberg AN, Hensley LE, Hoenen T, Honko AN, Ignatyev GM, Jahrling PB, Johnson KM, Klenk HD, Kobinger G, Lackemeyer MG, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Palacios G, Patterson JL, Paweska JT, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire EO, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, Towner JS, van der Groen G, Volchkov VE, Volchkova VA, Wahl-Jensen V, Warren TK, Warfield KL, Weidmann M, Nichol ST.

Arch Virol. 2014 May;159(5):1229-37. doi: 10.1007/s00705-013-1877-2.

10.

[Practice guidelines for management of the difficult airway: update by the American Society of Anesthesiologists task force].

Enterlein G, Byhahn C; American Society of Anesthesiologists Task Force..

Anaesthesist. 2013 Oct;62(10):832-5. doi: 10.1007/s00101-013-2222-6. German.

PMID:
24104949
11.

The L-VP35 and L-L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals.

Trunschke M, Conrad D, Enterlein S, Olejnik J, Brauburger K, Mühlberger E.

Virology. 2013 Jul 5;441(2):135-45. doi: 10.1016/j.virol.2013.03.013.

12.

Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae.

Kuhn JH, Bao Y, Bavari S, Becker S, Bradfute S, Brister JR, Bukreyev AA, Caì Y, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Gonzalez JP, Formenty P, Freiberg AN, Hensley LE, Honko AN, Ignatyev GM, Jahrling PB, Johnson KM, Klenk HD, Kobinger G, Lackemeyer MG, Leroy EM, Lever MS, Lofts LL, Mühlberger E, Netesov SV, Olinger GG, Palacios G, Patterson JL, Paweska JT, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire EO, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, Towner JS, van der Groen G, Volchkov VE, Wahl-Jensen V, Warren TK, Warfield KL, Weidmann M, Nichol ST.

Arch Virol. 2013 Jun;158(6):1425-32. doi: 10.1007/s00705-012-1594-2. No abstract available.

13.

Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae.

Kuhn JH, Bao Y, Bavari S, Becker S, Bradfute S, Brister JR, Bukreyev AA, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Hensley LE, Honko AN, Jahrling PB, Johnson KM, Kobinger G, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Palacios G, Patterson JL, Paweska JT, Pitt L, Radoshitzky SR, Saphire EO, Smither SJ, Swanepoel R, Towner JS, van der Groen G, Volchkov VE, Wahl-Jensen V, Warren TK, Weidmann M, Nichol ST.

Arch Virol. 2013 Jan;158(1):301-11. doi: 10.1007/s00705-012-1454-0. No abstract available.

14.

Biophysical characterization and conformational stability of Ebola and Marburg virus-like particles.

Hu L, Trefethen JM, Zeng Y, Yee L, Ohtake S, Lechuga-Ballesteros D, Warfield KL, Aman MJ, Shulenin S, Unfer R, Enterlein SG, Truong-Le V, Volkin DB, Joshi SB, Middaugh CR.

J Pharm Sci. 2011 Dec;100(12):5156-73. doi: 10.1002/jps.22724.

PMID:
21858822
15.

Identification of essential filovirion-associated host factors by serial proteomic analysis and RNAi screen.

Spurgers KB, Alefantis T, Peyser BD, Ruthel GT, Bergeron AA, Costantino JA, Enterlein S, Kota KP, Boltz RC, Aman MJ, Delvecchio VG, Bavari S.

Mol Cell Proteomics. 2010 Dec;9(12):2690-703. doi: 10.1074/mcp.M110.003418.

16.

Antiviral activity of a small-molecule inhibitor of filovirus infection.

Warren TK, Warfield KL, Wells J, Enterlein S, Smith M, Ruthel G, Yunus AS, Kinch MS, Goldblatt M, Aman MJ, Bavari S.

Antimicrob Agents Chemother. 2010 May;54(5):2152-9. doi: 10.1128/AAC.01315-09.

17.

Development of a broad-spectrum antiviral with activity against Ebola virus.

Aman MJ, Kinch MS, Warfield K, Warren T, Yunus A, Enterlein S, Stavale E, Wang P, Chang S, Tang Q, Porter K, Goldblatt M, Bavari S.

Antiviral Res. 2009 Sep;83(3):245-51. doi: 10.1016/j.antiviral.2009.06.001.

PMID:
19523489
18.

The marburg virus 3' noncoding region structurally and functionally differs from that of ebola virus.

Enterlein S, Schmidt KM, Schümann M, Conrad D, Krähling V, Olejnik J, Mühlberger E.

J Virol. 2009 May;83(9):4508-19. doi: 10.1128/JVI.02429-08.

20.

VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice.

Enterlein S, Warfield KL, Swenson DL, Stein DA, Smith JL, Gamble CS, Kroeker AD, Iversen PL, Bavari S, Mühlberger E.

Antimicrob Agents Chemother. 2006 Mar;50(3):984-93.

Items per page

Supplemental Content

Loading ...
Support Center